Cite
HARVARD Citation
Shaw, A. et al. (n.d.). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet oncology. 18 (7), pp. 874-886. [Online].